KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Common Equity (2016 - 2026)

Biogen has reported Common Equity over the past 18 years, most recently at $18.7 billion for Q1 2026.

  • For Q1 2026, Common Equity rose 9.85% year-over-year to $18.7 billion; the TTM value through Mar 2026 reached $18.7 billion, up 9.85%, while the annual FY2025 figure was $18.3 billion, 9.22% up from the prior year.
  • Common Equity for Q1 2026 was $18.7 billion at Biogen, up from $18.3 billion in the prior quarter.
  • Over five years, Common Equity peaked at $18.7 billion in Q1 2026 and troughed at -$171.2 million in Q3 2025.
  • A 5-year average of $14.3 billion and a median of $14.8 billion in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: rose 22.87% in 2023 and later tumbled 101.05% in 2025.
  • Year by year, Common Equity stood at $13.4 billion in 2022, then grew by 10.54% to $14.8 billion in 2023, then rose by 12.95% to $16.7 billion in 2024, then increased by 9.22% to $18.3 billion in 2025, then rose by 2.16% to $18.7 billion in 2026.
  • Business Quant data shows Common Equity for BIIB at $18.7 billion in Q1 2026, $18.3 billion in Q4 2025, and -$171.2 million in Q3 2025.